US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Birth Control

2,570.11

-21.8853-0.84%

Number of Gainers:3

Number of Losers:2

Number of Flat:- -

PE:- -

High:2,642.93

Open:2,568.44

Low:2,549.31

Close:2,592.00

Volume:7.25M

Turnover:172.45M

Market Cap:41.31B

Float Cap:40.47B

Loading ...

Femasys receives AMA CPT Editorial Panel approval for new CPT code

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application

FDA clears Daré Bioscience IND for DARE-HPV Phase 2 study

DarÉ Bioscience Announces FDA Clearance of Ind for Phase 2 Clinical Study of Dare-Hpv, a Potential Treatment for Persistent High-Risk Hpv Infection, the Most Common Cause of Cervical Cancer

THOMSON REUTERS

Teva Pharmaceutical Says FDA Accepts New Drug Application for Olanzapine in Schizophrenia Treatment

MT Newswires Live

FDA accepts Teva NDA for olanzapine extended-release injectable suspension

BRIEF-Corcept Says US Court Rules Teva's Generic Korlym Does Not Infringe Corcept Patents

Corcept Therapeutics Inc - Ruling Affirms December 2023 Verdict by Federal District Court

THOMSON REUTERS

Corcept Therapeutics Inc - Considering Judicial Review of Court Decision

THOMSON REUTERS

Corcept Provides Update on Patent Dispute With Teva Pharmaceuticals

THOMSON REUTERS

MannKind CEO Michael Castagna to Present at Oppenheimer Healthcare Life Sciences Conference

Veru CEO Mitchell Steiner to Present at Oppenheimer Healthcare Life Sciences Conference

MannKind Corporation Schedules Webcast to Review Financial Results and Business Update

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Femasys Inc. Files Initial Beneficial Ownership Statement for CTO Jeremy Alexander Sipos

Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

Benzinga_recent_news

Teva and Sanofi’s duvakitug Phase 2b data shows efficacy in colitis and Crohn’s

BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease

Teva: Duvakitug Was Well Tolerated and Safety Was Consistent With Induction Study

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":2570.1104,"timestamp":1771880399999,"preClose":2591.9956,"halted":0,"volume":7253916,"delay":0,"changeRate":-0.008443,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-21.885254,"latestTime":"02-23 16:00:00 EST","open":2568.4363,"high":2642.9292,"low":2549.3086,"amount":172450761.265304,"amplitude":0.036119,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771923600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.281475,"peRate":30.210268,"turnoverRate":0.004798,"increases":3,"decrements":2,"flats":0,"marketCap":41311216278,"floatMarketCap":40465980364},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2642.9292,"amplitude":0.036119,"preClose":2591.9956,"low":2549.3086,"pbRate":"5.281475","latestPrice":2570.1104,"volume":7253916,"delay":0,"open":2568.4363,"prevYearClose":2379.9924,"prevWeekClose":2591.9956,"prevMonthClose":2591.3975,"prevQuarterClose":2379.9924,"fiveDayClose":2576.6284,"twentyDayClose":2420.6091,"sixtyDayClose":1903.596,"secType":"PLATE","market":"US","turnoverRate":0.004798,"peRate":30.210268,"marketCap":41311216278,"floatMarketCap":40465980364,"timestamp":1771880399999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":3,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613780698","title":"Femasys receives AMA CPT Editorial Panel approval for new CPT code","url":"https://stock-news.laohu8.com/highlight/detail?id=2613780698","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613780698?lang=en_us&edition=fundamental","pubTime":"2026-02-23 22:06","pubTimestamp":1771855606,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announced that it has received notice from the American Medical Association, AMA, CPT Editorial Panel approving a new Category III C...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-receives-ama-cpt-editorial-panel-approval-for-new-cpt-code-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-receives-ama-cpt-editorial-panel-approval-for-new-cpt-code-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","FEMY","BK4082","BK4539","AMA","BK4585","BK4588","BK4215","CPT"],"gpt_icon":0},{"id":"2613709787","title":"Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination","url":"https://stock-news.laohu8.com/highlight/detail?id=2613709787","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613709787?lang=en_us&edition=fundamental","pubTime":"2026-02-23 22:00","pubTimestamp":1771855200,"startTime":"0","endTime":"0","summary":"-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb.  23, 2026  (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/23/3242685/0/en/Femasys-Receives-AMA-CPT-Editorial-Panel-Approval-for-New-Category-III-CPT-Code-for-FemaSeed-Intratubal-Insemination.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","AMA","ITI","CPT","BK4157","FEMY","BK4588","BK4585","BK4539","BK4584","BK4215","III","IVF","BK4134"],"gpt_icon":0},{"id":"2613480787","title":"FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2613480787","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613480787?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:48","pubTimestamp":1771854480,"startTime":"0","endTime":"0","summary":"Teva Pharmaceuticals Industries Ltd  on Friday announced that the U.S. Food and Drug Administration  has accepted its New Drug Application  for olanzapine extended-release injectable suspension.The marketing application for TEV-‘749 is based on results from the Phase 3 SOLARIS trial, which demonstrated an efficacy and safety profile consistent with currently available olanzapine formulations.This investigational drug aims to improve treatment adherence for individuals living with schizophrenia, addressing a critical gap in care.In the SOLARIS trial, TEV-‘749 was administered as a once-monthly subcutaneous injection, showing no evidence for the need for post-injection monitoring, which is typically required for other formulations.The acceptance of this NDA marks a significant milestone for Teva as it seeks to provide a long-acting option for patients who rely on olanzapine.TEV-‘749 utilizes SteadyTeq, a copolymer technology proprietary to Medincell that provides a controlled, steady, su","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/23/Brain-to-Heart-Growth.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/23/Brain-to-Heart-Growth.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/fda/26/02/50777798/fda-accepts-tevas-new-long-acting-schizophrenia-treatment-application","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/02/50777798/fda-accepts-tevas-new-long-acting-schizophrenia-treatment-application","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4584","TEVA","BK4596","BK4566","BK4588","BK4007","LU1983299246.USD","BK4585","BK4217","BK4559","BK4557","LU2324357040.USD","SMA"],"gpt_icon":0},{"id":"2613719784","title":"FDA clears Daré Bioscience IND for DARE-HPV Phase 2 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2613719784","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613719784?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:00","pubTimestamp":1771851644,"startTime":"0","endTime":"0","summary":"Daré Bioscience Inc. said the U.S. Food and Drug Administration cleared its Investigational New Drug  application for DARE-HPV, allowing the company to begin a planned Phase 2 clinical study in women with persistent high-risk HPV infection. The company also said the DARE-HPV program is supported by a $10 million contract funded by the Advanced Research Projects Agency for Health , with $6.5 million received to date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL8H26w9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DARE","SG9999014021.USD","BK4584","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014039.USD","BK4588","IE00BKPKM429.USD","SG9999014013.SGD","LU2095319765.USD","NDAQ","SG9999014005.SGD","BK4585","BK4007","BK4112"],"gpt_icon":0},{"id":"2613978422","title":"DarÉ Bioscience Announces FDA Clearance of Ind for Phase 2 Clinical Study of Dare-Hpv, a Potential Treatment for Persistent High-Risk Hpv Infection, the Most Common Cause of Cervical Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2613978422","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613978422?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:00","pubTimestamp":1771851603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nTUA26SNK0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","DARE","BK4007"],"gpt_icon":0},{"id":"2613829408","title":"Teva Pharmaceutical Says FDA Accepts New Drug Application for Olanzapine in Schizophrenia Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2613829408","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613829408?lang=en_us&edition=fundamental","pubTime":"2026-02-21 04:05","pubTimestamp":1771617940,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries  said Friday that the US Food and Drug Administration has accepted the company's New Drug Application for olanzapine extended-release injectable suspension, or TEV-'749, for the treatment of schizophrenia in adults.The application for TEV-'749 is based on results from the phase 3 Solaris trial that demonstrated an efficacy and safety profile consistent with other available olanzapine formulations, and showed no evidence for the need for post-injection monitoring, Teva Pharmaceutical Industries said.Shares of the company were down over 1% in recent Friday trading.Price: 34.00, Change: -0.33, Percent Change: -0.96","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LU2324357040.USD","BK4584","BK4596","BK4585","BK4557","BK4588","BK4559","LU1983299246.USD","TEVA","BK4566"],"gpt_icon":0},{"id":"2613129475","title":"FDA accepts Teva NDA for olanzapine extended-release injectable suspension","url":"https://stock-news.laohu8.com/highlight/detail?id=2613129475","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613129475?lang=en_us&edition=fundamental","pubTime":"2026-02-21 03:55","pubTimestamp":1771617319,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Medincell announced that the U.S. Food and Drug Administr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-accepts-teva-nda-for-olanzapine-extended-release-injectable-suspension-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-accepts-teva-nda-for-olanzapine-extended-release-injectable-suspension-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4596","BK4566","BK4557","BK4588","BK4585","TEVA","LU2324357040.USD","BK4559","BK4007","LU1983299246.USD","BK4584"],"gpt_icon":0},{"id":"2612929235","title":"BRIEF-Corcept Says US Court Rules Teva's Generic Korlym Does Not Infringe Corcept Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2612929235","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612929235?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:35","pubTimestamp":1771536943,"startTime":"0","endTime":"0","summary":"BRIEF-Corcept Says US Court Rules Teva's Generic Korlym Does Not Infringe Corcept PatentsFeb 19 (Reuters) - Corcept Therapeutics Inc CORT.O:CORCEPT PROVIDES UPDATE ON PATENT DISPUTE WITH TEVA PHARMACE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUABQN0YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4588","BK4596","TEVA","CORT","BK4007","BK4532","BK4557","LU1983299246.USD","BK4566","BK4585","BK4559","LU2324357040.USD","BK4584","LU0566484027.USD"],"gpt_icon":0},{"id":"2612728001","title":"Corcept Therapeutics Inc - Ruling Affirms December 2023 Verdict by Federal District Court","url":"https://stock-news.laohu8.com/highlight/detail?id=2612728001","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612728001?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:00","pubTimestamp":1771534800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUABQN0YZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4557","BK4007","LU0566484027.USD","LU1983299246.USD","LU2324357040.USD","BK4532","TEVA","BK4559","LU1559883803.SGD","BK4585","BK4596","BK4584","BK4588","BK4566","CORT"],"gpt_icon":0},{"id":"2612280046","title":"Corcept Therapeutics Inc - Considering Judicial Review of Court Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2612280046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612280046?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:00","pubTimestamp":1771534800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUABQN0YZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","TEVA","LU1983299246.USD","BK4596","LU1559883803.SGD","BK4566","BK4559","CORT","BK4532","BK4584","LU0566484027.USD","BK4557","LU2324357040.USD","BK4007","BK4588"],"gpt_icon":0},{"id":"2612044280","title":"Corcept Provides Update on Patent Dispute With Teva Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2612044280","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612044280?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:00","pubTimestamp":1771534800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUABQN0YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TEVA","BK4532","CORT","LU1983299246.USD","BK4584","BK4588","BK4596","BK4559","LU2324357040.USD","LU0566484027.USD","BK4566","LU1559883803.SGD","BK4557","BK4007","BK4585"],"gpt_icon":0},{"id":"2612288748","title":"MannKind CEO Michael Castagna to Present at Oppenheimer Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2612288748","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612288748?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:02","pubTimestamp":1771509725,"startTime":"0","endTime":"0","summary":"MannKind CEO Michael Castagna to Present at Oppenheimer Healthcare Life Sciences Conference               MannKind Corporation (Nasdaq: MNKD) said CEO Michael Castagna will present and provide busines","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL8LLrCh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU2210149790.SGD","MNKD","BK4112","LU2095319765.USD","SG9999014021.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014039.USD","BK4584","IE00BGHQF748.EUR","LU0314104364.USD","BK4585","BK4139","IE00B64PRP62.GBP","NDAQ","SG9999014005.SGD","BK4588"],"gpt_icon":0},{"id":"2612729400","title":"Veru CEO Mitchell Steiner to Present at Oppenheimer Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2612729400","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612729400?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:32","pubTimestamp":1771507976,"startTime":"0","endTime":"0","summary":"Veru CEO Mitchell Steiner to Present at Oppenheimer Healthcare Life Sciences Conference               Veru Inc. (NASDAQ: VERU) said its Chairman, President and CEO Mitchell Steiner, M.D., will present","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL601bSZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4557","IE00BKPKM429.USD","NDAQ","SG9999014039.USD","VERU","IE00B64PRP62.GBP","BK4183","BK4007","BK4588","BK4584","BK4112","SG9999014005.SGD","SG9999014021.USD","LU0314104364.USD","LU2095319765.USD","SG9999014013.SGD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2612544961","title":"MannKind Corporation Schedules Webcast to Review Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2612544961","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612544961?lang=en_us&edition=fundamental","pubTime":"2026-02-18 22:00","pubTimestamp":1771423256,"startTime":"0","endTime":"0","summary":"MannKind Corporation Schedules Webcast to Review Financial Results and Business Update               MannKind Corporation said it will release its fourth quarter and full year 2025 financial results b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL1t6dlP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","SG9999014013.SGD","LU2095319765.USD","SG9999014005.SGD","BK4112","BK4584","IE00BKPKM429.USD","BK4139","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014039.USD","BK4588","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4585","NDAQ"],"gpt_icon":0},{"id":"2612415894","title":"MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612415894","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612415894?lang=en_us&edition=fundamental","pubTime":"2026-02-18 22:00","pubTimestamp":1771423200,"startTime":"0","endTime":"0","summary":"Investor Relations. Kate Miranda. (617) 921-5461. Email: ir@mnkd.com. Media Relations. Christie Iacangelo. (818) 292-3500. Email: media@mnkd.com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240267/29517/en/MannKind-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-26-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNKD","BK4584"],"gpt_icon":0},{"id":"2612947496","title":"Femasys Inc. Files Initial Beneficial Ownership Statement for CTO Jeremy Alexander Sipos","url":"https://stock-news.laohu8.com/highlight/detail?id=2612947496","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612947496?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:46","pubTimestamp":1771368367,"startTime":"0","endTime":"0","summary":"Femasys Inc. has filed an initial statement of beneficial ownership. The filing lists Jeremy Alexander Sipos, Chief Technology Officer, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL5lTjFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Femasys Inc. Files Initial Beneficial Ownership Statement for CTO Jeremy Alexander Sipos","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4584","BK4539","FEMY"],"gpt_icon":0},{"id":"2612745489","title":"Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2612745489","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612745489?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:04","pubTimestamp":1771329840,"startTime":"0","endTime":"0","summary":"Teva stock rises after a new study, in partnership with Sanofi, shows lasting benefits in ulcerative colitis and Crohn's patients.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/17/Teva-Pharmaceuticals.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/17/Teva-Pharmaceuticals.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/large-cap/26/02/50645029/teva-pharmaceuticals-new-study-shows-lasting-relief-for-inflammatory-bowel-disease-patients","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/large-cap/26/02/50645029/teva-pharmaceuticals-new-study-shows-lasting-relief-for-inflammatory-bowel-disease-patients","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4559","BK4217","LU2324357040.USD","BK4566","BK4588","BK4585","SMA","LU1983299246.USD","TEVA","SNY","BK4584","IE00BFXG1179.USD","BK4557","BK4596","BK4007"],"gpt_icon":0},{"id":"2612456221","title":"Teva and Sanofi’s duvakitug Phase 2b data shows efficacy in colitis and Crohn’s","url":"https://stock-news.laohu8.com/highlight/detail?id=2612456221","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612456221?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:16","pubTimestamp":1771326961,"startTime":"0","endTime":"0","summary":"Teva (TEVA) and Sanofi (SNY) announced positive results from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human mono...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-and-sanofis-duvakitug-phase-2b-data-shows-efficacy-in-colitis-and-crohns-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-and-sanofis-duvakitug-phase-2b-data-shows-efficacy-in-colitis-and-crohns-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","IE00BFXG1179.USD","TEVA","BK4596","SNY","LU1983299246.USD","BK4559","BK4588","LU2324357040.USD","BK4584","BK4566","BK4585","BK4557","SNYNF"],"gpt_icon":0},{"id":"2612456940","title":"BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2612456940","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612456940?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:09","pubTimestamp":1771326599,"startTime":"0","endTime":"0","summary":"BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's DiseaseFeb 17 (Reuters) - Sanofi SA SASY.PA:SANOFI AND TEVA’S DUVAKITUG PHASE 2B MAINTENANCE DATA DEMONSTRAT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUAM4KSY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4584","BK4557","LU2324357040.USD","LU1983299246.USD","BK4559","TEVA","BK4596","BK4585","BK4566","BK4007"],"gpt_icon":0},{"id":"2612563414","title":"Teva: Duvakitug Was Well Tolerated and Safety Was Consistent With Induction Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2612563414","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612563414?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:00","pubTimestamp":1771326001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA8BNFHC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LU2324357040.USD","BK4596","BK4584","BK4557","LU1983299246.USD","TEVA","BK4588","BK4566","BK4585","BK4559"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}]}}